Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

DraftKings (NASDAQ: DKNG) is forecasting robust growth in revenue and profitability in 2025. Read More: Earn up to $845 cash ...

Chandan Taparia has recommended three stocks to buy today – Infosys, Bank of Baroda, and Power Finance Corporation ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

The brokerage reiterated its 'Buy' rating on the stock with a revised target price of Rs 2,235. When comparing Hyundai Motor ...

CNQ stock is down in recent months. Is a rebound on the way next year? The post Is CNQ Stock a Buy, Sell, or Hold for 2025?

Hindalco shares: Hindalco reported a 123% year-on-year (YoY) rise in standalone net profit, amounting to Rs 1,891 crore.

Management is looking to close the gap between a plausible sum-of-the-parts valuation and its share price through asset sales and repurchases of its own stock. If the Vision ... investment is passive ...

Shares of FMCG player Britannia Industries tumbled 4% to an intraday low of Rs 5,220 on the BSE; Should you invest?

Choosing a Stock Market Strategy That Fits Your ... strategy must always be at the switch and ready to buy and sell. Profits ...